Product Name |
5-HT6 Receptor |
5-HT1 Receptor |
5-HT2 Receptor |
5-HT3 Receptor |
5-HT5 Receptor |
5-HT7 Receptor |
5-HT4 Receptor |
5-HT6 Receptor Selectivity |
Purity |
Idalopirdine Hydrochloride |
5-HT6 Receptor, Ki: 0.83 nM
|
|
|
|
|
|
|
Selective Antagonist
|
99.83% |
Intepirdine |
5-HT6 Receptor, pKi: 9.63
|
|
|
|
|
|
|
Selective Antagonist
|
98.92% |
SB 271046 Hydrochloride |
5-HT6 Receptor, pKi: 8.92-9.02
|
5-HT1D Receptor, pKi: 6.55
5-HT1A Receptor, pKi: 6.35
5-HT1B Receptor, pKi: 6.05
5-HT1F Receptor, pKi: 5.95
5-HT1E Receptor, pKi: <4.99
|
5-HT2A Receptor, pKi: 5.62
5-HT2B Receptor, pKi: 5.41
Human 5-HT2C Receptor, pKi: 5.73
|
|
|
5-HT7 Receptor, pKi: 5.39
|
5-HT4 Receptor, pKi: 5.27
|
Selective Antagonist
|
99.06% |
WAY-181187 |
5-HT6 Receptor, Ki: 2.2 nM
5-HT6 Receptor, EC50: 6.6 nM
|
|
|
|
|
|
|
Selective Agonist
|
98.05% |
NPS ALX Compound 4a |
5-HT6 Receptor, IC50: 7.2 nM
5-HT6 Receptor, Ki: 0.2 nM
|
|
|
|
|
|
|
Selective Antagonist
|
>99.0% |
Masupirdine mesylate |
5-HT6 Receptor, Ki: 2.04 nM
|
|
|
|
|
|
|
Selective Antagonist
|
|
AVN-492 |
5-HT6 Receptor, Ki: 91 pM
|
|
|
|
|
|
|
Pan Antagonist
|
99.49% |
Olanzapine |
|
|
5-HT2A Receptor, Ki: 4 nM
5-HT2C Receptor, Ki: 11 nM
|
5-HT3 Receptor, Ki: 57 nM
|
|
|
|
Pan Antagonist
|
99.89% |
Methiothepin mesylate |
5-HT6 Receptor, pKd: 8.74
|
5-HT1A Receptor, pKd: 7.10
5-HT1B Receptor, pKd: 7.28
5-HT1C Receptor, pKd: 7.56
5-HT1D Receptor, pKd: 6.99
|
5-HT2A Receptor, pKi: 8.50
5-HT2B Receptor, pKi: 8.68
5-HT2C Receptor, pKi: 8.35
|
|
5-HT5A Receptor, pKd: 7.0
5-HT5B Receptor, pKd: 7.8
|
5-HT7 Receptor, pKd: 8.99
|
|
Pan Antagonist
|
99.32% |
Blonanserin |
5-HT6 Receptor, Ki: 11.7 nM
|
|
5-HT2A Receptor, Ki: 0.812 nM
5-HT2C Receptor, Ki: 26.4 nM
|
|
|
|
|
Pan Antagonist
|
99.77% |
GSK163090 |
Human 5-HT6 Receptor, pKi: <5.3
|
5-HT1A Receptor, pKi: 9.4
5-HT1B Receptor, pKi: 8.5
5-HT1D Receptor, pKi: 9.7
|
5-HT2A Receptor, pKi: 6
5-HT2B Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 5.8
|
|
|
Human 5-HT7 Receptor , pKi: 6.8
|
|
Pan Antagonist
|
99.95% |
RS-127445 hydrochloride |
|
|
5-HT2A Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 6.4
5-HT2B Receptor, pKi: 9.5
|
|
|
|
|
Pan Antagonist
|
99.68% |
Asenapine |
|
5-HT1A Receptor, pKi: 8.6
5-HT1B Receptor, pKi: 8.4
|
5-HT2A Receptor, pKi: 10.2
5-HT2C Receptor, pKi: 10.5
5-HT2B Receptor, pKi: 9.8
|
|
|
|
|
Pan Antagonist
|
98.81% |
BRL 54443 |
5-HT6 Receptor, Ki: >10,000 nM
|
5-HT1E Receptor, Ki: 1.1 nM
5-HT1F Receptor, Ki: 0.7 nM
5-HT1A Receptor, Ki: 63 nM
5-HT1B Receptor, Ki: 126 nM
5-HT1D Receptor, Ki: 63 nM
|
5-HT2A Receptor, Ki: 1259 nM
5-HT2B Receptor, Ki: 100 nM
5-HT2C Receptor, Ki: 316 nM
|
|
|
5-HT7 Receptor, Ki: >10,000 nM
|
|
Pan Agonist
|
99.39% |
Iloperidone |
Rat 5-HT6 Receptor, Ki: 42.7 μM
|
Rat 5-HT1A Receptor, Ki: 168 nM
|
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
|
|
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
|
Pan Antagonist
|
99.64% |
Nuciferine |
5-HT6 Receptor, EC50: 700 nM
|
5-HT1A Receptor, EC50: 3.2 μM
|
5-HT2C Receptor, IC50: 131 nM
5-HT2A Receptor, IC50: 478 nM
5-HT2B Receptor, IC50: 1 μM
|
|
|
5-HT7 Receptor, IC50: 150 nM
|
|
Pan Modulator
|
99.66% |
SB-399885 hydrochloride |
|
|
|
|
|
|
|
Pan Antagonist
|
98.93% |
SB 243213 dihydrochloride |
Human 5-HT6 Receptor, pKi: 6.5
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
Pan Antagonist
|
>99.0% |
SB 243213 hydrochloride |
Human 5-HT6 Receptor, pKi: 6.5
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
Pan Antagonist
|
|
5-HT6/7 antagonist 1 |
|
|
|
|
|
|
|
Pan Antagonist
|
|
SB 243213 |
Human 5-HT6 Receptor, pKi: 6.5
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
Pan Antagonist
|
98.62% |
Ro 04-6790 |
Rat 5-HT6 Receptor, pKi: 7.26
Human 5-HT6 Receptor, pKi: 7.35
|
|
|
|
|
|
|
Pan Antagonist
|
|
BGC20-761 |
Human 5-HT6 Receptor, Ki: 20 nM
|
|
Human 5-HT2A Receptor, Ki: 69 nM
|
|
|
|
|
Pan Antagonist
|
|
Iloperidone hydrochloride |
Rat 5-HT6 Receptor, Ki: 42.7 nM
|
Rat 5-HT1A Receptor, Ki: 168 nM
|
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
|
|
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
|
Pan Antagonist
|
|